Haemonetics Corp

Haemonetics shares soar 17% after CSL Plasma partnership, unlocking new revenue streams and driving analysts to raise targets—learn why this deal powers future earnings.

Explore Haemonetics: Boston‑based leader in automated blood processing, $4.81 B market cap, high P/E, and global tech innovation.

Haemonetics releases Q1 FY 2027 results, highlighting strong vascular closure tech gains and a promising VASCADE MVP® XL study.

Haemonetics Q3 2026 earnings preview: discover revenue outlook, product pipeline, and analyst insights before the Feb 5 webcast.

Haemonetics CEO Chris Simon to present at the 44th J.P. Morgan Healthcare Conference, detailing growth, innovation and market outlook for the blood‑processing leader.

Haemonetics Q2 2026 earnings rise 14.3% to $38.68M, boost stock to $50.72 and lift BTIG price target to $88 – strong outlook for blood‑processing solutions.

Haemonetics Corporation, a leading healthcare technology company, is poised for success with a strong market position, positive analyst expectations, and a focus on innovation in automated blood processing systems.

Haemonetics Corporation reported robust revenue growth in Q4 2025, driven by strategic shifts and a commitment to innovation in the medical technology sector.

Haemonetics Corporation reported robust revenue growth in Q4 2025, driven by strategic shifts and a commitment to innovation in the medical technology sector.

Haemonetics Corp, a leader in automated blood processing systems, is under scrutiny from analysts as its stock price fluctuates, with some expressing optimism about its long-term growth potential despite short-term challenges.